What drove BeiGene's revenue growth in 2023?

Growth came mainly from product sales, which rose 75% to $2.19 billion for the year. BRUKINSA global sales were $1.3 billion (up 129%), and the U.S. became the largest market at $1.1 billion, up from $502.6 million in 2022. Tislelizumab sales grew to $536.6 million and in-licensed Amgen products to $188.3 million.

Is BeiGene closer to profitability?

Operating results improved sharply. The adjusted operating loss fell to $752 million from $1.42 billion, and gross margin rose to 82.7%. However, the company is not yet profitable at the operating level, and the reported GAAP net loss of $881.7 million was reduced by a one-time $362.9 million gain from the BMS arbitration settlement.

How strong is the company's balance sheet and cash position?

Cash, equivalents, restricted cash and short-term investments totaled $3.19 billion at December 31, 2023, down from $4.54 billion a year earlier. Operating cash outflow was $1.16 billion for the year, and debt increased to $886 million from $538 million. Investors should watch the pace of cash burn against the company's continued R&D and manufacturing investment.

What are the key regulatory catalysts for 2024?

Management targets an FDA decision in March 2024 on BRUKINSA with obinutuzumab for relapsed or refractory follicular lymphoma, and several tislelizumab decisions, including FDA action on second-line ESCC in the first half of 2024 and first-line ESCC with a target PDUFA date in July 2024. These are company expectations and remain subject to regulatory outcomes.

Why did GAAP net loss improve so much, and is that improvement sustainable?

Net loss improved mainly from reduced operating losses and a $362.9 million non-operating gain tied to the BMS arbitration settlement recognized in 2023. The settlement gain is non-recurring, so investors should focus on the operating loss trend, which improved by about $555 million on a GAAP basis, rather than the headline net loss.

ONC/BEIGF 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 26, 2024. Cited figures are marked; the original filing is the authoritative source.

BeiGene, Ltd. (now BeOne Medicines, ticker ONC) reported fourth-quarter and full-year 2023 results on February 26, 2024.

Total revenue reached $634.4 million^a in Q4 and $2.46 billion for the full year, up 67% and 74% year over year. Growth was driven by BRUKINSA, whose global sales were $413.0 million in Q4 and $1.3 billion for the year, up 135% and 129%. U.S. revenue more than doubled to $1.1 billion for 2023, and management expects U.S. BRUKINSA sales to keep growing in 2024.

Profitability improved substantially. Gross margin on product sales was 82.7% for the year, versus 77.2% in 2022. GAAP operating loss narrowed to $1.21 billion^b from $1.79 billion, and adjusted operating loss narrowed to $752 million from $1.42 billion.

The GAAP net loss of $881.7 million^c ($0.65 per share) was flattered by a $362.9 million non-operating gain from the BMS arbitration settlement, so the underlying operating loss is the better measure of run-rate performance. Operating cash burn was still about $1.2 billion for 2023, and cash, equivalents, restricted cash and short-term investments fell to $3.19 billion from $4.54 billion, while debt rose to $886 million from $538 million. The filing also lays out 2024 catalysts, including a targeted March 2024 FDA decision on BRUKINSA with obinutuzumab in relapsed/refractory follicular lymphoma, several tislelizumab approval decisions across ESCC and NSCLC, and the expected July 2024 operational date for the Princeton, New Jersey biologics facility.

Note that Item 2.02 results are furnished, while the Item 8.01 pipeline and milestone content is filed. These forward-looking milestones are management expectations and carry regulatory and execution risk.

02—Key points

Key Highlights

Total revenue rose 74% to $2.46 billion for FY2023 and 67% to $634.4 million in Q4, with product revenue of $2.19 billion for the year (up 75%).
BRUKINSA global sales reached $1.3 billion in FY2023 (up 129%), and U.S. revenue grew to $1.1 billion from $502.6 million, making the U.S. the largest market.
Adjusted operating loss narrowed to $752 million for FY2023 from $1.42 billion (down 47%), and GAAP operating loss narrowed 33% to $1.21 billion, reflecting operating leverage.
Gross margin on product sales expanded to 82.7% for FY2023 from 77.2%, driven by higher BRUKINSA mix and lower unit costs.
GAAP net loss improved to $881.7 million ($0.65 per share) from $2.0 billion, but this includes a $362.9 million non-operating gain from the BMS arbitration settlement.
Liquidity declined: cash, equivalents, restricted cash and short-term investments were $3.19 billion at year-end versus $4.54 billion, with operating cash use of $1.16 billion and debt up to $886 million.
2024 catalysts include a targeted March 2024 FDA decision on BRUKINSA plus obinutuzumab in R/R follicular lymphoma and multiple tislelizumab approval decisions, plus the Princeton, NJ biologics plant expected to be operational in July 2024.

03—Questions

Frequently Asked Questions

What drove BeiGene's revenue growth in 2023?
Growth came mainly from product sales, which rose 75% to $2.19 billion for the year. BRUKINSA global sales were $1.3 billion (up 129%), and the U.S. became the largest market at $1.1 billion, up from $502.6 million in 2022. Tislelizumab sales grew to $536.6 million and in-licensed Amgen products to $188.3 million.
Is BeiGene closer to profitability?
Operating results improved sharply. The adjusted operating loss fell to $752 million from $1.42 billion, and gross margin rose to 82.7%. However, the company is not yet profitable at the operating level, and the reported GAAP net loss of $881.7 million was reduced by a one-time $362.9 million gain from the BMS arbitration settlement.
How strong is the company's balance sheet and cash position?
Cash, equivalents, restricted cash and short-term investments totaled $3.19 billion at December 31, 2023, down from $4.54 billion a year earlier. Operating cash outflow was $1.16 billion for the year, and debt increased to $886 million from $538 million. Investors should watch the pace of cash burn against the company's continued R&D and manufacturing investment.
What are the key regulatory catalysts for 2024?
Management targets an FDA decision in March 2024 on BRUKINSA with obinutuzumab for relapsed or refractory follicular lymphoma, and several tislelizumab decisions, including FDA action on second-line ESCC in the first half of 2024 and first-line ESCC with a target PDUFA date in July 2024. These are company expectations and remain subject to regulatory outcomes.
Why did GAAP net loss improve so much, and is that improvement sustainable?
Net loss improved mainly from reduced operating losses and a $362.9 million non-operating gain tied to the BMS arbitration settlement recognized in 2023. The settlement gain is non-recurring, so investors should focus on the operating loss trend, which improved by about $555 million on a GAAP basis, rather than the headline net loss.

04—Continue

← View all 8-K filings